Stay updated on GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe study page now displays a 403 Forbidden error screen, preventing access to the study details. The usual page content and navigation are replaced by the error UI, indicating an access restriction rather than actual study information.SummaryDifference16%

- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a new site version deployment. This change appears to be a general platform update rather than content modification to the study record.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5. This signals a minor update to the page's build or content.SummaryDifference0.1%

- Check67 days agoChange DetectedPage revision updated from v3.6.3 to v3.6.4, representing a new release of the page template/content. This appears to be a routine deployment without changes to study data or primary information.SummaryDifference0.1%

- Check88 days agoChange DetectedRevision: v3.6.3 was added and v3.6.2 removed, indicating a minor, system-wide update to the study record on ClinicalTrials.gov. This update does not alter the study content, eligibility criteria, or outcomes.SummaryDifference0.1%

- Check96 days agoChange DetectedThe page's revision stamp was updated from v3.6.0 to v3.6.2, indicating a newer version of the page. This update updates the page tracking without changing the study details presented.SummaryDifference0.1%

Stay in the know with updates to GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GMI-1359 Safety in HR+ Metastatic Breast Cancer Clinical Trial page.